Skip to main content
Clinical Trials/NCT04560504
NCT04560504
Completed
Not Applicable

Oculomotor Deficits in Parkinson's Disease: Enhancing Eye Movement Performance and Dynamic Visual Acuity With Oculomotor Training Using a Pilot Randomized Clinical Trial Design

The Hong Kong Polytechnic University1 site in 1 country27 target enrollmentSeptember 3, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
The Hong Kong Polytechnic University
Enrollment
27
Locations
1
Primary Endpoint
Smooth Vergence eye movements
Status
Completed
Last Updated
last year

Overview

Brief Summary

Parkinson's disease (PD) is a common neurodegenerative disorder which is characterized by both motor and non-motor symptoms and usually affects people aged 50 years or above. Many studies showed eye movement deficits and visual changes in patients with PD.

Previous studies have also indicated that clinical eye movement training could enhance the functional performance of patients with various eye movement problems resulting from ocular and neurodegenerative diseases.

In this study, we will investigate the effectiveness of eye movement training on dynamic vision and functional performance in PD patients with oculomotor deficits.

Registry
clinicaltrials.gov
Start Date
September 3, 2020
End Date
December 1, 2022
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Allen MY Cheong

Associate Professor

The Hong Kong Polytechnic University

Eligibility Criteria

Inclusion Criteria

  • Parkinson's Disease diagnosed by a neurologist or geriatrician with the range of Stage
  • 1 to 4 (Hoehn and Yahr Classification)
  • Able to speak and comprehend Cantonese dialect
  • Able to travel independently

Exclusion Criteria

  • Any congenital eye problem (e.g. congenital strabismus or amblyopia in either eye) or any manifest eye diseases (e.g. macular degeneration, glaucoma, etc)
  • Severe medical problems (e.g. stroke)
  • Cognitive impairment (e.g. dementia)
  • Presence of any psychiatric or neurological diseases (apart from Parkinson's disease) or receiving of any psychoactive pharmacological treatment
  • Receiving any medication that is known to affect eye movement and cognitive function
  • Previous formal vision rehabilitation or oculomotor intervention

Outcomes

Primary Outcomes

Smooth Vergence eye movements

Time Frame: Change from baseline at week 4 and change from baseline at week 12

Smooth vergence eye movement is measured using a head-mounted eye tracking while fixating at an approaching target moving at different speeds

Secondary Outcomes

  • Sentence reading performance(Change from baseline at week 4 and change from baseline at week 12)
  • Oculomotor characteristics(Change from baseline at week 4 and change from baseline at week 12)
  • Passage reading performance(Change from baseline at week 4 and change from baseline at week 12)

Study Sites (1)

Loading locations...

Similar Trials